Master of Science in Business Administration and Economics from the Uppsala University. Has 25 years of experience as CFO alongside with growth related operational responsibilities. He has been working under private equity regimes as well as in both listed and privately held companies, e.g CFO assignments at the Phadia group, 2005-2011, as well as Iggesund Paperboard, Trelleborg Industries and Observer/Cision. Today he is the Chairman of Tellacq AB and Bioservo Technologies AB and member of the Board of Antrad Medical, Motion Display and Secure Appbox.
Dependent in relation to the company's major owners.
Entry: 2016
Holding: 1 551 021 shares as well as 1 600 warrants
Kerstin Valinder Strinnholm has many years of experience in sales, marketing, and business development from senior positions at Astra/AstraZeneca and Nycomed/Takeda including EVP Business Development for the Nycomed Group. Currently Kerstin is a board member of Moberg Pharma AB, Camurus AB, KVS Invest AB, Immedica AB, Promore Pharma AB and Cavastor AB. She holds a degree from the School of Journalism at the University of Gothenburg.
Independent in relation to the company and the company's major owners.
Entry: 2021
Holding: 100 000 shares
Margit Alt Murphy is Associate Professor in Experimental Rehabilitation Medicine at University of Gothenburg and Senior University Hospital Specialist Physiotherapist at Sahlgrenska University Hospital. Margit is a leading researcher in the field of stroke rehabilitation and arm and hand function. She has over 40 publications and has received multiple awards for her research. In addition, Margit is working with new technologies to support patients recovering from a stroke including wearable sensors in smart textiles and EMG augmented VR feedback. She holds a PhD in Medical Science from the Institute for Neuroscience and Physiology at University of Gothenburg.
Independent in relation to the company and the company's major owners.
Entry: 2021
Holding: No shares
Master of Science in Economics from the Stockholm School of Economics as well as the Copenhagen Business School. Nikolaj is currently President and CEO of Orexo AB, a publicly Swedish specialty pharmaceutical company. Nikolaj has been CEO of Orexo AB since 2013 and has contributed to the establishment of Orexo in the US and the transformation of Orexo from development companies to a company in a commercial phase. Before Orexo, he has worked many years in senior positions and as an advisor in life science in Sweden and internationally.
Independent in relation to the company and the company's major owners.
Entry: 2019
Holding: 15 100 shares
Master of Science in Business from Lund University, Sweden. Background in accounting at various accounting firms. CFO at Nycomed Pharma AS from 1997 until 2011. Currently, Runar is COB of ConceptoMed AS, a Norwegian MedTech Company and is Board member of Bioservo Technologies AB, Norsk Kjededrift AS, SE Holding AS and acts as a consultant and member of the Audit Committee of Acino, a Swiss Pharmaceutical Company.
Dependent in relation to the company's major owners.
Entry: 2016
Holding: 1 600 warrants